Back to today’s briefing

Story perspectives

Sarepta Faces $250M Loss, Restructures Amid Safety Concerns

8/7/2025

42 8

Summary

Story summary

Sarepta Therapeutics is grappling with a staggering net loss of $250.6 million in Q2 2025, largely due to safety issues and tragic patient deaths associated with its gene therapy, Elevidys. In response, the company is restructuring, which includes layoffs and a pivot towards small interfering RNA, all while burdened with over $1 billion in looming debt due by 2027.

1 of 1

Story summary

Sarepta Therapeutics is grappling with a staggering net loss of $250.6 million in Q2 2025, largely due to safety issues and tragic patient deaths associated with its gene therapy, Elevidys. In response, the company is restructuring, which includes layoffs and a pivot towards small interfering RNA, all while burdened with over $1 billion in looming debt due by 2027.